BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 14, 2015 at 3.10 p.m.
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act
Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on December 12, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Versant Ventures V, LLC on behalf of itself and Versant Venture Capital V, L.P. as a result of the implementation of changes to the transparency directive in the Finnish Securities Market Act.
According to the notification, the total number of Biotie shares owned directly or through financial instruments by Versant Ventures V, LLC and its funds was 8.80 per cent of Biotie's total number of shares and voting rights on 26 November 2015. Biotie's registered total number of shares and voting rights amounting to 1,086,940,271 has been used in the calculation of percentages for the announcement.
Total positions of Versant Ventures V, LLC and its funds subject to the notification:
| % of shares and voting rights (total of A) | % of shares and voting rights through financial instruments (total of B) | Total of both in % (A + B) | |
| Resulting situation on the date on which threshold was crossed or reached | 5.39 | 3.41 | 8.80 |
| Position of previous notification (if applicable) | 5.97 | N/A | N/A |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
| Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| Shares (FI0009011571) | - | 37,051,651 | - | 3.41 |
| Shares (FI0009011571) represented by 268,672 ADSs | - | 21,493,760 | - | 1.98 |
| SUBTOTAL A | 58,545,411 | 5.39 | ||
For further information on the ADSs representing the Company's shares, the notification refers to the stock exchange release issued by the Company on June 11, 2015.
B: Financial instruments according to SMA 9:6a
| Type of financial instrument | Expiration date | Exercise/ Conversion period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| Warrants entitling to shares (new or treasury shares) (FI0009011571) | Nov 1, 2020 | Nov 1, 2015 - Nov 1, 2020 | Physical settlement | 37,051,651 | 3.41 |
| SUBTOTAL B | 37,051,651 | 3.41 |
For further information on the warrants, the notification refers to the stock exchange release issued by the Company on April 23, 2015.
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| Versant Ventures V, LLC | 0 | 0 | 0 |
| Versant Venture Capital V, L.P. | 4.73 | 2.99 | 7.72 |
| Versant Affiliates Fund V, L.P. | 0.14 | 0.09 | 0.23 |
| Versant Ophthalmic Affiliates Fund I, L.P. | 0.16 | 0.10 | 0.26 |
| Versant Ventures V GP-GP (Canada), Inc. | 0 | 0 | 0 |
| Versant Ventures V (Canada), L.P. | 0 | 0 | 0 |
| Versant Venture Capital V (Canada) LP | 0.36 | 0.23 | 0.59 |
According to the notification, Versant Ventures V, LLC is the sole general partner of (i) Versant Venture Capital V, L.P., (ii) Versant Affiliates Fund V, L.P. and (iii) Versant Ophthalmic Affiliates Fund I, L.P. and (iv) the sole shareholder of Versant Ventures V GP-GP (Canada), Inc. Versant Ventures V GP-GP (Canada), Inc. is the sole general partner of Versant Ventures V (Canada), L.P., which is the sole general partner of Versant Venture Capital V (Canada) LP. Neither Versant Ventures V, LLC nor any other entity under its control, other than (i) Versant Venture Capital V, L.P., (ii) Versant Affiliates Fund V, L.P., (iii) Versant Ophthalmic Affiliates Fund I, L.P. and (iv) Versant Venture Capital V (Canada) LP, holds any shares or financial instruments in the Company.
In Turku, December 14, 2015
Biotie Therapies Corp.
Timo Veromaa President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
DISTRIBUTION:
NASDAQ OMX Helsinki Ltd Main Media www.biotie.com
HUG#1973305
